LifeVantage's In Vitro Study Shows Increase In GLP-1 Production, Stock Up

(RTTNews) - LifeVantage Corp. (LFVN), Tuesday announced promising results of an in vitro study, investigating the combined effects of its upcoming two-product system on activating GLP-1 production, a critical hormone in weight management and glucose regulation.

The study demonstrated an increase in GLP-1 production and a synergistic activation of the key genes responsible for its synthesis and regulation.

"We are excited by the scientific evidence supporting the claims of our new GLP-1 system and we are thrilled to be able to introduce the this system beginning in October," said Steve Fife, President and CEO of the company.

Currently, LifeVantage's stock is trading at $9.26, up 8.56 percent on the Nasdaq.